Tarsus Pharmaceuticals (TARS) Operating Income (2019 - 2026)

Tarsus Pharmaceuticals' Operating Income history runs 8 years deep, the most recent figure standing at -$6.1 million for Q1 2026.

• In Q1 2026, Operating Income rose 76.7% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$50.8 million (up 53.45% YoY), while the FY2025 annual figure was -$71.0 million, up 41.14% from the prior year.
• Operating Income was -$6.1 million for Q1 2026 at Tarsus Pharmaceuticals, up from -$8.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$5.2 million in Q2 2022 to a low of -$44.4 million in Q4 2023.
• Historically, Operating Income has averaged -$23.7 million across 5 years, with a median of -$24.4 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Operating Income tumbled 528.27% in 2023, then jumped 76.7% in 2026.
• A 5-year view of Operating Income shows it stood at -$15.1 million in 2022, then slumped by 195.13% to -$44.4 million in 2023, then surged by 45.06% to -$24.4 million in 2024, then soared by 67.34% to -$8.0 million in 2025, then gained by 23.24% to -$6.1 million in 2026.
• The last three Operating Income figures came in at -$6.1 million (Q1 2026), -$8.0 million (Q4 2025), and -$14.5 million (Q3 2025), per Business Quant data.